This is the latest episode of the free narrated DDW podcast, “CROs and targeted protein degradation offer an exciting future”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “CROs: Drug discovery expertise on hand” and “Why the emergence of targeted protein degradation is so exciting”.
In the first article, Lu Rahman asks Laura Hinton, Operations Director at Gentronix, to offer some insight into the contract research organisation (CRO) market and how Gentronix is making its presence known in this sector.
In the second article, Lu Rahman finds out more about a new translational research centre which was established last year to bolster the University of Dundee’s drug discovery position. The Centre for Targeted Protein Degradation (CeTPD) would allow Professor Alessio Ciulli and colleagues to expand their pioneering work in an area that has attracted billions of pounds of investment.